Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International (KNSA) has reported Work In Process for 3 consecutive years, with $18.3 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Work In Process rose 189.26% year-over-year to $18.3 million; the trailing twelve-month figure through Dec 2023 stood at $18.3 million (up 189.26% YoY), and the FY2023 full-year result was $18.3 million, up 189.26% from the prior year.
• Work In Process climbed to $18.3 million in Q4 2023 per KNSA's latest filing, from $13.4 million in the prior quarter.
• Across five years, Work In Process topped out at $18.3 million in Q4 2023 and bottomed at $148000.0 in Q1 2022.
• Historically, Work In Process has averaged $8.3 million across 3 years, with a median of $6.5 million in 2022.
• The widest YoY moves for Work In Process: up 9033.11% in 2023, down 189.26% in 2023.
• Over 3 years, Work In Process stood at $4.2 million in 2021, then surged by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
• According to Business Quant data, Work In Process over the past three periods registered $18.3 million, $13.4 million, and $6.6 million for Q4 2023, Q3 2023, and Q2 2023 respectively.